Embecta (NASDAQ:EMBC) Issues FY 2025 Earnings Guidance

Embecta (NASDAQ:EMBC) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 2.700-2.900 for the period, compared to the consensus earnings per share estimate of 2.810. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Embecta Stock Performance

Shares of NASDAQ EMBC traded down $0.54 during midday trading on Friday, reaching $17.19. The stock had a trading volume of 174,604 shares, compared to its average volume of 371,965. Embecta has a twelve month low of $9.93 and a twelve month high of $21.48. The company’s 50 day moving average price is $19.65 and its 200 day moving average price is $16.53. The firm has a market cap of $999.02 million, a price-to-earnings ratio of 12.81, a price-to-earnings-growth ratio of 0.97 and a beta of 1.20.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.20. Embecta had a negative return on equity of 18.54% and a net margin of 6.97%. Equities analysts forecast that Embecta will post 2.84 earnings per share for the current fiscal year.

Embecta Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 18th. Stockholders of record on Friday, December 6th were given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 3.49%. The ex-dividend date was Friday, December 6th. Embecta’s dividend payout ratio (DPR) is 44.44%.

Analysts Set New Price Targets

EMBC has been the topic of a number of research reports. Morgan Stanley raised shares of Embecta from an “underweight” rating to an “equal weight” rating and increased their target price for the stock from $13.00 to $20.00 in a research note on Monday, December 2nd. BTIG Research upgraded Embecta from a “neutral” rating to a “buy” rating and set a $26.00 target price for the company in a research note on Wednesday, November 27th.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.